Articles
22.06.2022
EU Joint HTA: How should manufacturers adapt to th...

EUnetHTA and the EU Joint HTA Process EUnetHTA was established in 2006 to facilitate information sha...

Read more
Articles
21.06.2022
Seeking early advice from the EMA and multiple HTA...

Introduction Achieving access to patients for innovative treatments is becoming a significant challe...

Read more
Insider Insights
20.06.2022
NICE trials new proportionate approach to increase

The aim of this trial is to increase capacity, with a goal of a 20% increase by 2023-24.

Read more
Articles
07.06.2022
EU Joint HTA: What’s going on and what does it m...

EUnetHTA and the EU Joint HTA Process Originally set up in 2006, EUnetHTA was established to facilit...

Read more
Insider Insights
26.05.2022
G-BA awards highest rating to Trodelvy

The drug was judged to offer an indication of major additional benefit in adult patients with advanc...

Read more
Articles
25.05.2022
Is Saudi Arabia the indicator for change in the Mi...

Introduction For some manufacturers, launching in the Middle East and North Africa (MENA) is fraught...

Read more
Insider Insights
20.05.2022
Improving market access for new drugs

With respects to pricing and reimbursement, the societies reportedly call for the criteria that led ...

Read more
News
18.05.2022
PMA Insights: Week 20

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Articles
11.05.2022
How are countries in South-East Asia establishing ...

Introduction Health Technology Assessment (HTA) implementation has been historically slow in Asia co...

Read more
04.05.2022
PMA Insights: Week 18

A short, 60 seconds read that summarises 4 handpicked articles that are worth reading about: Regulat...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.